PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation
Saved in:
Published in | Clinical lymphoma, myeloma and leukemia Vol. 13; p. S384 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
01.09.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
ISSN: | 2152-2650 2152-2669 |
---|---|
DOI: | 10.1016/j.clml.2013.07.098 |